Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways

Ali, Naveid A; Wu, Jianmin; Hochgräfe, Falko; Chan, Howard; Nair, Radhika; Ye, Sunny; Zhang, Luxi; Lyons, Ruth J; Pinese, Mark; Lee, Hong Ching; Armstrong, Nicola; Ormandy, Christopher J; Clark, Susan J; Swarbrick, Alexander; Daly, Roger J

doi:10.1186/s13058-014-0437-3

Table 1 Top ten pathways/biological processes for each tumour type ^a

From: Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways

Term	CorrectedP-value	Accession	Gene name
p53
Leucocyte transendothelial migration	7.87E-05	P70460\|Q61140\|P26040\|P26041\|Q64727\|Q8VI36\|P57780\|Q7TPR4\|P09055	Vasp\|Bcar1\|Ezr\|Msn\|Vcl\|Pxn\|Actn4\|Actn1\|Itgb1
Bacterial invasion of epithelial cells	<0.01	P22682\|Q61140\|Q64727\|Q8VI36\|Q9JM76\|P49817\|P09055	Cbl\|Bcar1\|Vcl\|Pxn\|Arpc3\|Cav1\|Itgb1
Regulation of actin cytoskeleton	<0.01	Q61140\|P26040\|P26041\|Q7TPR4\|Q64727\|Q8VI36\|P26043\|P57780\|Q9JM76\|P09055	Bcar1\|Ezr\|Msn\|Actn1\|Vcl\|Pxn\|Rdx\|Actn4\|Arpc3\|Itgb1
Focal adhesion	<0.01	P70460\|P26039\|Q61140\|Q64727\|Q8VI36\|P57780\|Q7TPR4\|P49817\|P09055	Vasp\|Tln1\|Bcar1\|Vcl\|Pxn\|Actn4\|Actn1\|Cav1\|Itgb1
Muscle contraction	<0.01	P62204\|Q64727\|P20152\|Q8VI36\|P26039	Calm1\|Vcl\|Vim\|Pxn\|Tln1
Haemostasis	<0.01	P12023\|P20491\|P26039\|Q61140\|Q91YI4\|P14234\|P48025\|P57780\|Q7TPR4\|P49817\|P09055	App\|Fcer1g\|Tln1\|Bcar1\|Arrb2\|Fgr\|Sykb\|Actn4\|Actn1\|Cav1\|Itgb1
Fcγ receptor–mediated phagocytosis	0.02	Q9JM76\|P70460\|P08103\|Q9ES52\|P48025	Arpc3\|Vasp\|Hck\|Inpp5d\|Sykb
Adherens junction	0.05	Q9D358\|P57780\|Q7TPR4\|Q64727	Acp1\|Actn4\|Actn1\|Vcl
Cell–cell communication	0.05	Q80W68\|Q9QXS1\|Q7TPR4\|P09055\|Q3UND0	Kirrel\|Plec\|Actn1\|Itgb1\|Skap2
Endocytosis	0.12	P22682\|Q91YI4\|P01899\|Q99LI8\|Q62351\|P49817	Cbl\|Arrb2\|H2-D1\|Hgs\|Tfrc\|Cav1
Her2
ErbB signalling pathway	3.79E-02	P70424\|Q01279\|P47941\|P22682\|Q62077	Erbb2\|Egfr\|Crkl\|Cbl\|Plcγ1
Disease	0.09	Q99LI8\|P35235\|Q01279\|P22682\|Q62077	Hgs\|Ptpn11\|Egfr\|Cbl\|Plcγ1
Non–small-cell lung cancer	0.16	P70424\|Q01279\|Q62077	Erbb2\|Egfr\|Plcγ1
Pathways in cancer	0.16	P22682\|Q62077\|P47941\|Q01279\|P26618\|P70424\|P97807	Cbl\|Plcγ1\|Crkl\|Egfr\|Pdgfrα\|Erbb2\|Fh1
Glioma	0.16	Q62077\|Q01279\|P26618	Plcγ1\|Egfr\|Pdgfrα
Focal adhesion	0.16	P70424\|Q01279\|P47941\|P26039\|P26618	Erbb2\|Egfr\|Crkl\|Tln1\|Pdgfrα
Renal cell carcinoma	0.16	P35235\|P47941\|P97807	Ptpn11\|Crkl\|Fh1
Neurotrophin signalling pathway	0.16	O08911\|P35235\|P47941\|Q62077	Mapk12\|Ptpn11\|Crkl\|Plcγ1
Chronic myeloid leukaemia	0.16	P35235\|P47941\|P22682	Ptpn11\|Crkl\|Cbl
Developmental biology	0.16	P35235\|P70424\|Q01279\|P26039\|Q62077	Ptpn11\|Erbb2\|Egfr\|Tln1\|Plcγ1
PyMT
Type 2 diabetes mellitus	3.08E-02	P35569\|Q64143\|Q63844\|P26450\|P28867	Irs1\|Pik3r3\|Mapk3\|Pik3r1\|Prkcd
FcεRI signalling pathway	0.03	P28867\|Q63844\|P25911\|Q64143\|Q9Z1B7\|P26450	Prkcd\|Mapk3\|Lyn\|Pik3r3\|Mapk13\|Pik3r1
Acute myeloid leukaemia	0.03	Q64143\|Q63844\|P05532\|P26450\|P42227	Pik3r3\|Mapk3\|Kit\|Pik3r1\|Stat3
Fcγ receptor–mediated phagocytosis	0.04	P28867\|Q63844\|P08103\|Q64143\|P25911\|P26450	Prkcd\|Mapk3\|Hck\|Pik3r3\|Lyn\|Pik3r1
Neurotrophin signalling pathway	0.04	P35569\|P28867\|Q63844\|Q64143\|Q9Z1B7\|Q9QYY0\|P26450	Irs1\|Prkcd\|Mapk3\|Pik3r3\|Mapk13\|Gab1\|Pik3r1
Aldosterone-regulated sodium reabsorption	0.04	P35569\|Q64143\|Q63844\|P26450	Irs1\|Pik3r3\|Mapk3\|Pik3r1
ErbB signalling pathway	0.09	Q9QYY0\|Q63844\|P26450\|Q61526\|Q64143	Gab1\|Mapk3\|Pik3r1\|Erbb3\|Pik3r3
Cell–cell communication	0.10	Q80W68\|P30999\|P26450\|Q9Z1B7	Kirrel\|Ctnnd1\|Pik3r1\|Mapk13
Hepatitis C	0.10	Q63844\|Q9Z0G9\|Q64143\|Q9Z1B7\|P42227\|P26450	Mapk3\|Cldn3\|Pik3r3\|Mapk13\|Stat3\|Pik3r1
Chemokine signalling pathway	0.12	P28867\|Q63844\|P08103\|Q64143\|P42227\|P25911\|P26450	Prkcd\|Mapk3\|Hck\|Pik3r3\|Stat3\|Lyn\|Pik3r1

^aPyMT: Polyoma virus middle T antigen. Significantly enriched terms are shown in bold.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us